Candel Therapeutics is a clinical-stage biotech developing viral immunotherapies designed to stimulate anti-tumor immune responses. Its pipeline centers on engineered oncolytic viruses intended for solid tumors and other cancers. The company partners with clinical sites and collaborators to advance candidates through early- and mid-stage trials rather than selling commercial products today.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | 7.4 | — |
| Q2 2025 | 0 | — | -4.8 | — |
| Q3 2025 | 0 | — | -11.3 | — |
| Q4 2025 | 0 | — | -29.5 | — |
| Q1 2026 | 0 | — | -8.9 | -220.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Immix Biopharma, Inc. (IMMX), Horizon Bancorp, Inc. (HBNC), QuidelOrtho Corporation (QDEL), American Bitcoin Corp (ABTC), NANO Nuclear Energy Inc. (NNE), Aebi Schmidt Holding AG (AEBI)